Clindamycin Phosphate Inject · #27 of 35 active shortages by FDA posting duration
Brand: CLINDAMYCIN PHOSPHATE
FDA lists Clindamycin Phosphate Inject as Active Shortage (Baxter Healthcare).
Availability on file: Limited Availability
Clindamycin Phosphate Injection: Active Shortage
Limited Availability 25 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Clindamycin Phosphate Injection
- Manufacturer
- Baxter Healthcare
- Dosage Form
- Injection
- Presentation
- Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)
- Package NDC
- 0338-9553-50
Status & Timeline
- Status
- Active Shortage
- Availability
- Limited Availability
- First Reported
- Mar 21, 2023
- Last Updated
- Mar 4, 2026
- Therapeutic Category
- Anti-Infective
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Estimated recovery: April 2026
Full Drug Profile
clindamycin
Side effects, interactions, warnings & more
Nearby, Other Clindamycin Shortage Records
Clindamycin Phosphate Injection
Sandoz Inc.
Injection
Clindamycin Phosphate Injection
Sandoz Inc.
Injection
Clindamycin Phosphate Injection
Sandoz Inc.
Injection
Clindamycin Phosphate Injection
Sandoz Inc.
Injection
Clindamycin Phosphate Injection
Sagent Pharmaceuticals
Injection
Clindamycin Phosphate Injection
Sagent Pharmaceuticals
Injection
FDA reason on file: Estimated recovery: April 2026. General shortage guidance lives on the tracker hub.